Overview of the Market

The Japan Point-of-Care Diagnostics Market size reached a valuation of approximately US$832.04 million in 2024 and is expected to grow significantly to US$1,925.62 million by 2033, exhibiting a compound annual growth rate (CAGR) of about 9.8% during the forecast period 2025-2033, according to DataM Intelligence. Point-of-care diagnostics involve medical testing performed near or at the site of patient care rather than centralized laboratories to offer rapid, accurate diagnostic results. Japan’s aging population, rising prevalence of chronic diseases such as diabetes and cardiovascular disorders, as well as increasing awareness towards early disease detection, are key market drivers. The shift toward decentralized diagnostics enables timely clinical decisions, reducing hospital visits and healthcare burdens while improving patient outcomes.

Japan’s advanced healthcare infrastructure and high expenditure on healthcare accelerate POC diagnostics’ adoption. Technological innovations such as miniaturized portable devices, multi-parameter testing platforms, and integration with digital health and telemedicine applications are further transforming the market. Infectious disease testing products dominate due to Japan’s heightened focus on disease surveillance and rapid outbreak containment, especially post-COVID-19. Additionally, growth in chronic disease management fuels demand for glucose meters and cardiovascular monitoring tests. The market also benefits from government initiatives promoting diagnostic innovations and preventive healthcare across clinical and home settings.

𝗚𝗲𝘁 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗨𝘀𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗘𝗺𝗮𝗶𝗹 𝗜𝗗 𝗳𝗼𝗿 𝗮 𝗤𝘂𝗶𝗰𝗸 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲): https://www.datamintelligence.com/download-sample/japan-point-of-care-diagnostics-market

Market Segmentation

By Product (Infectious Disease Testing Products, Blood Glucose Products, Blood Gas & Electrolyte Products, Urinalysis Products, Hematology Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Profiling Products, Drug-of-Abuse Products, Others)
By Technology (Lateral Flow Assays, Immunoassays, Molecular Diagnostics, Microfluidics, Others)
By Application (Infectious Diseases, Cardiology, Oncology, Endocrinology, Hematology, Neurology, Drug Testing, Others)
By End-User (Hospitals & Clinics, Diagnostic Laboratories, Home Care Settings, Ambulatory Surgery Centers (ASCs))

Market Share

Japan commands a significant share within the Asia-Pacific POC diagnostics market, attributable to its technologically advanced healthcare system and high patient health awareness. The infectious disease segment leads the market with rapid diagnostic tests for viruses and bacterial infections, essential for infection control and prevention. Glucose monitoring remains a strong revenue contributor given the rising diabetic population. Hospitals represent the largest end-user space due to demand for bedside diagnostics, but the home care segment is expanding fast as aging patients seek self-management tools. The commercial presence of domestic and global companies continuously intensifies competition and innovation within the market.

Market Drivers

The key drivers of Japan’s POC diagnostics market include demographic shifts toward an elderly population with multiple comorbidities requiring continuous care and monitoring. Technological advancements yield increasingly compact, accurate, user-friendly diagnostic devices suitable for point-of-care and remote use. Growing government initiatives encouraging early disease detection, health screenings, and decentralized healthcare facilitate market expansion. Increased awareness of infectious diseases and the need for rapid testing during pandemics have accelerated the adoption of molecular and immunoassay platforms. Rising investment in telemedicine and digital health infrastructure also supports integration of POC diagnostics into broader healthcare networks. These factors combined create a conducive environment for sustained market growth.

Key Players

Key companies operating in the Japan point-of-care diagnostics market include:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Sekisui Medical Co., Ltd.
• Cepheid Inc.
• BioMérieux SA
• TAUNS Laboratories, Inc.
• Fujirebio Holdings, Inc.
• Nova Biomedical Corporation
• Becton, Dickinson and Company
• Qiagen N.V.

Recent Developments in 2025

In early 2025, Nova Biomedical introduced new portable glucose monitoring devices with improved accuracy and data integration options for clinical and home use.

In April 2023, QIAGEN announced the launch of its QIAstat-Dx syndromic testing system in Japan, featuring a SARS-CoV-2 respiratory panel enhancing rapid viral pathogen detection capabilities.

Conclusion

The Japan point-of-care diagnostics market is set for steady growth driven by an aging population, technological innovation, and heightened awareness of early disease detection. Infectious disease testing remains a critical segment, while expansion in chronic disease diagnostics fuels broader adoption. The continuous integration of POC diagnostics with digital health platforms and telemedicine furthers the decentralization of healthcare services, increasing accessibility and convenience for patients and providers alike. Major pharmaceutical and medical device firms are actively innovating, launching advanced products to capture share in this evolving market. Collectively, these dynamics position Japan as a significant and expanding market in the global point-of-care diagnostics landscape.

About DataM Intelligence:

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us:

Company Name: DataM Intelligence 4market Research LLP

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com